Your browser doesn't support javascript.
loading
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Zhang, Lu; Poland, Bill; Green, Michelle; Wong, Shekman; Slatter, J Greg.
Affiliation
  • Zhang L; Certara Integrated Drug Development, Princeton, NJ, USA.
  • Poland B; Certara Integrated Drug Development, Princeton, NJ, USA.
  • Green M; Certara Integrated Drug Development, Princeton, NJ, USA.
  • Wong S; Kartos Therapeutics, Inc., Redwood City, CA, USA.
  • Slatter JG; Kartos Therapeutics, Inc., Bellevue, WA, USA.
Xenobiotica ; 52(6): 555-566, 2022 Jun.
Article in En | MEDLINE | ID: mdl-36052821
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glucuronides Limits: Animals / Humans Language: En Journal: Xenobiotica Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glucuronides Limits: Animals / Humans Language: En Journal: Xenobiotica Year: 2022 Document type: Article Affiliation country: Country of publication: